MANIFESTATION OF THE PARTICULARITIES OF SOME KEY ISSUE ASPECTS OF NEW IMMUNOTHERAPY CHALLENGES AND PERSPECTIVES BY CAR-T CELL THERAPY
DOI:
https://doi.org/10.52340/jecm.2024.04.32Ключевые слова:
New Immunotherapy, Challenges, Perspectives, CAR-T Cell therapyАннотация
Aim of the research was to study and analyze particularities of some key issue aspects of new immunotherapy challenges and perspectives by CAR-T Cell Therapy. Cancer immunotherapy encompasses a broad spectrum of therapeutic approaches, each directed towards distinct components of the immune system or the tumor microenvironment. Major categories include: Monoclonal Antibodies (mAbs): These engineered antibodies target cancer cell antigens, inducing immune mediated destruction through mechanisms like antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CAR-T cell therapy, a revolutionary cancer treatment, offers potentially long-lasting response in patients with challenging hematologic cancers, by genetically modifying a patient’s own T cells to express chimeric antigen receptors (CARs), enabling them to identify and attack the cancerous cells without major histocompatibility complex (MHC) restrictions.
Скачивания
Библиографические ссылки
Levine, B. L., Miskin, J., Wonnacott, K., Keir, C., Global, L. (2016). Global manufacturing of CAR T cell therapy. Molecular Therapy – Methods & Clinical Development, 4, 92–101.
Zah, E., Lin, M. Y., (2016). T Cells Expressing CD19/CD20 Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. Cancer Immunology Research, 4(6), 498–508.
Guedan, S., Calderon, H., Posey, A. D., Maus, M. V., (2019). Engineering and Design of Chimeric Antigen Receptors. Molecular Therapy, Methods & Clinical Development, 12, 145–156.
Maus, M. V., June, C. H. (2016). Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. Clinical Cancer Research, 22(8), 1875–1884.
June, C. H., Sadelain, M. (2018). Chimeric Antigen Receptor Therapy. New England Journal of Medicine, 379(1), 64–73.
Maude, S. L., Laetsch, T. W. (2018). Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine, 378(5), 439–448.
Schuster, S. J., Bishop, M. R. (2019). Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 380(1), 45–56.
Locke, F. L., Ghobadi, A. (2019). Long-term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-cell Lymphoma, Multicentre, The Lancet Oncology, 20(1), 31–42.
Neelapu, S. S., Locke, F. L. (2017). Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine, 377(26), 2531–2544.
Загрузки
Опубликован
Как цитировать
Выпуск
Раздел
